Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
3.750
-0.190 (-4.82%)
Jun 5, 2026, 11:53 AM EDT - Market open
Aardvark Therapeutics Employees
Aardvark Therapeutics had 40 employees as of March 31, 2026. The number of employees increased by 14 or 53.85% compared to the same quarter last year.
Employees
40
Change
14
Growth
53.85%
Revenue / Employee
n/a
Profits / Employee
-$1,746,725
Market Cap
81.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 40 | 14 | 53.85% | 40 | 0 |
| Dec 31, 2025 | 40 | 18 | 81.82% | 40 | 0 |
| Sep 30, 2025 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2025 | 31 | 17 | 121.43% | 31 | 0 |
| Mar 31, 2025 | 26 | 12 | 85.71% | 26 | 0 |
| Dec 31, 2024 | 22 | - | - | 22 | 0 |
| Sep 30, 2024 | 18 | - | - | 17 | 1 |
| Jun 30, 2024 | 14 | - | - | 12 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| ImmuCell | 73 |
| Rani Therapeutics Holdings | 71 |
| NeurAxis | 24 |
| Atara Biotherapeutics | 14 |
| Rallybio | 14 |
| ProMIS Neurosciences | 11 |
AARD News
- 8 days ago - Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS - PRNewsWire
- 20 days ago - Aardvark Therapeutics downgraded to Underperform from Buy at BofA - TheFly
- 21 days ago - Aardvark Therapeutics price target lowered to $7 from $8 at B. Riley - TheFly
- 21 days ago - Aardvark Therapeutics Inc trading halted, volatility trading pause - TheFly
- 21 days ago - Aardvark Therapeutics Inc trading resumes - TheFly
- 21 days ago - Aardvark Therapeutics downgraded to Neutral from Buy at BTIG - TheFly
- 21 days ago - Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley - TheFly
- 21 days ago - Aardvark Therapeutics announces FDA clinical hold on ARD-101 - TheFly